Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis

H Eggemann; Cosima Brucker; M Schrauder; M Thill; F Flock; M Reinisch; SD Costa; A Ignatov

doi:10.1038/s41416-020-0857-z

Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis

H Eggemann, Cosima Brucker (Co-Autor/-in), M Schrauder, M Thill, F Flock, M Reinisch, SD Costa, A Ignatov

Universitätsklinik für Frauenheilkunde und Geburtshilfe

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

21 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	33-37
Fachzeitschrift	BRITISH JOURNAL OF CANCER
Jahrgang	123
Ausgabenummer	1
DOIs	https://doi.org/10.1038/s41416-020-0857-z
Publikationsstatus	Veröffentlicht - 2020

Zugriff auf Dokument

10.1038/s41416-020-0857-z

Dieses zitieren

Eggemann, H., Brucker, C., Schrauder, M., Thill, M., Flock, F., Reinisch, M., Costa, SD., & Ignatov, A. (2020). Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. BRITISH JOURNAL OF CANCER , 123(1), 33-37. https://doi.org/10.1038/s41416-020-0857-z

Eggemann, H ; Brucker, Cosima ; Schrauder, M et al. / Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. in: BRITISH JOURNAL OF CANCER 2020 ; Jahrgang 123, Nr. 1. S. 33-37.

@article{d7022646eb13461c9d801ba0d842345c,

title = "Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis",

keywords = "AROMATASE INHIBITOR",

author = "H Eggemann and Cosima Brucker and M Schrauder and M Thill and F Flock and M Reinisch and SD Costa and A Ignatov",

note = "Brucker: Breast Unit, Department of Obstetrics and Gynecology, Paracelsus Medical University, Klinikum N{\"u}rnberg, Germany ",

year = "2020",

doi = "10.1038/s41416-020-0857-z",

language = "English",

volume = "123",

pages = "33--37",

journal = "BRITISH JOURNAL OF CANCER ",

issn = "0007-0920",

publisher = "Springer Nature",

number = "1",

}

Eggemann, H, Brucker, C, Schrauder, M, Thill, M, Flock, F, Reinisch, M, Costa, SD & Ignatov, A 2020, 'Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis', BRITISH JOURNAL OF CANCER , Jg. 123, Nr. 1, S. 33-37. https://doi.org/10.1038/s41416-020-0857-z

Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. / Eggemann, H; Brucker, Cosima (Co-Autor/-in); Schrauder, M et al.
in: BRITISH JOURNAL OF CANCER , Jahrgang 123, Nr. 1, 2020, S. 33-37.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis

AU - Eggemann, H

AU - Brucker, Cosima

AU - Schrauder, M

AU - Thill, M

AU - Flock, F

AU - Reinisch, M

AU - Costa, SD

AU - Ignatov, A

N1 - Brucker: Breast Unit, Department of Obstetrics and Gynecology, Paracelsus Medical University, Klinikum Nürnberg, Germany

PY - 2020

Y1 - 2020

KW - AROMATASE INHIBITOR

U2 - 10.1038/s41416-020-0857-z

DO - 10.1038/s41416-020-0857-z

M3 - Original Article

C2 - 32367072

SN - 0007-0920

VL - 123

SP - 33

EP - 37

JO - BRITISH JOURNAL OF CANCER

JF - BRITISH JOURNAL OF CANCER

IS - 1

ER -

Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M et al. Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. BRITISH JOURNAL OF CANCER . 2020;123(1):33-37. doi: 10.1038/s41416-020-0857-z